Pullulan capsules

Information

  • Patent Grant
  • 11576870
  • Patent Number
    11,576,870
  • Date Filed
    Tuesday, April 10, 2018
    6 years ago
  • Date Issued
    Tuesday, February 14, 2023
    a year ago
Abstract
The instant disclosure provides a capsule composition comprising pullulan, a setting system and a surfactant system that is a sucroglyceride or a sugar fatty acid ester, and methods for making such capsules.
Description
FIELD

The present application relates to capsules comprising pullulan, to film forming compositions comprising pullulan, and to methods for making capsules.


SUMMARY

Hard and soft capsules comprising pullulan are known, Pullulan provides a number of advantages over other conventional capsule film forming polymers such as gelatin or hydroxypropyl methyl cellulose. Pullulan is a natural product of non animal origin made without the need for chemical modification. High product quality consistency can be obtained by controlling the fermentation process. The resulting films formed with pullulan have excellent homogeneity and transparency. In addition, such films have very low oxygen permeability. Accordingly, capsules made from pullulan are particularly useful for the filling of oxygen sensitive products such as fish and vegetable oils Such films and resulting capsules made from pullulan also have relatively low water content, and exhibit high stability over storage, such as with respect to mechanical and dissolution properties.


The natural origin of pullulan and its superior properties as a film forming material has made pullulan a desired polymer for the manufacture of capsules having ingredients of all natural origin. This would enable capsules made with pullulan to meet the requirements for “organic” labeling. Notwithstanding the commercial need for a capsule meeting the organic labeling requirements, no satisfactory pullulan capsules have to date been developed that meet the organic labeling requirements.


In one embodiment, a capsule comprises: pullulan in an amount of at least 70 wt % of the capsule; a setting system in an amount of at least 0.01 wt % of the capsule; and a surfactant comprising a sucroglyceride or a sugar fatty acid ester or mixture thereof. In one embodiment, the surfactant is present in an amount of at least 0.2 wt % of the capsule. The wt % amounts are exclusive of water present in the capsule.


In another embodiment, a capsule consists essentially of; pullulan in an amount of at least 70 wt % of the capsule; a setting system in an amount of at least 0.01 wt % of the capsule; and a surfactant selected from the group consisting of sucroglycerides, sugar fatty acid sugar esters, and mixtures thereof in an amount of at least 0.2 wt % of the capsule. The wt % amounts are exclusive of water present in the capsule.


In another embodiment, the pullulan used to manufacture the capsule is manufactured using an organic fermentation process.


In another embodiment, the sugar fatty acid ester comprises a sugar head group selected from the group consisting of glucose, fructose, galactose, sucrose, maltose, trehalose, lactose, and raffinose.


In another embodiment, the sucroglyceride or the sugar fatty acid ester comprises a lipophilic group derived from the fatty acid esters of a vegetable oil selected from the group consisting of coconut oil, palm oil, palmist oil, soy oil, rapeseed oil, sunflower oil, cottonseed oil, peanut oil, olive oil, canola oil, castor oil, corn oil, flaxseed oil, safflower oil, and sesame oil.


In another embodiment, the surfactant is a sucrose fatty acid ester.


In another embodiment, the surfactant is a sucroglyceride.


In another embodiment, the surfactant is derived from the fatty acids of coconut oil.


In another embodiment, the surfactant is sucrose cocoate.


In another embodiment, the surfactant is present in an amount of from 0.2 wt % to 2 wt % of the capsule composition, or from 0.4 wt % to 1.5 wt % of the capsule composition, or from 0.5 wt % to 1 wt % of the capsule composition (exclusive of water).


In another embodiment, the setting system comprises carrageenan, gellan or agar. In one embodiment, the setting system comprises carrageenan and cations. In another embodiment, the setting system comprises agar and cations.


In one embodiment, the capsules have a Ca2+ content of at least 200 mg/kg, or at least 300 mg/kg, or even at least 500 mg/kg.


In one embodiment, the capsules have a Mg2+ content of at least 30 mg/kg, or at least 40 mg/kg, or even at least 50 mg/kg.


In one embodiment, the capsules have a ratio of K+/(Mg2++Ca2+) that is less than 50, or less than 40, or less than 30, or even less than 20. In another embodiment, the capsule further comprises at least one sequestering agent.


In another embodiment, the capsule further comprising plasticizers or/and flavoring agents.


In another embodiment, the capsule further comprises coloring agents in a range from about 0% to 10% based upon the weight of the composition.


In another embodiment, the capsule comprises a coating.


In another embodiment, a caplet is encapsulated in the capsule.


In another embodiment, a method for manufacturing the capsule of claim 1 or 2, comprises:


a) providing an aqueous dipping composition comprising pullulan, the setting system, and the surfactant;


b) dipping mold pins in the aqueous dipping composition;


c) extracting the mold pins from the aqueous clipping composition such that a film is formed over each of the mold pins;


d) drying the film to form a solid coating on the mold pins;


e) removing the solid coating from the mold pins to provide capsule shells.


In another embodiment, the mold pins are lubricated with a mixture of lecithin and a vegetable oil.


In another embodiment, the solid coating is lubricated with a mixture of lecithin and a vegetable oil.


In another embodiment, the mold pins are lubricated with a sucroglyceride or sugar fatty acid ester. In another embodiment, the mold pins a lubricated with a mixture of a sucroglyceride and


In another embodiment, the lecithin is selected from the group consisting of soybean lecithin, peanut lecithin, cottonseed lecithin, sunflower lecithin, rapeseed lecithin, corn lecithin, and groundnut lecithin. In a preferred embodiment, the lecithin is sunflower lecithin.


In another embodiment, the vegetable oil is selected from the group consisting of coconut oil, palm oil, palmist oil, soy oil, rapeseed oil, sunflower oil, cottonseed oil, peanut oil, live oil, canals oil, castor oil, corn oil, flaxseed oil, safflower oil, and sesame oil.


In another embodiment, the lubricant comprises a mixture of coconut oil and sunflower lecithin.


It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are riot restrictive of the claimed subject matter.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a graph of pullulan biomass concentration and pullulan molecular weight versus time.



FIGS. 2A and 2B are bar graphs quantifying biomass (FIG. 2A) and yield (FIG. 2B) in the presence of MgSO4, 0.16 g/L MgCl2, or 0.32 g/L MgCl2.





DETAILED DESCRIPTION

Definitions


As used herein, reference to an element by the indefinite article “a” or “an” does not exclude the possibility that more than one of the element is present, unless the context clearly requires that there is one and only one of the elements. The indefinite article “a” or “an” thus usually means “at least one.” The disclosure of numerical ranges should be understood as referring to each discrete point within the range, inclusive of endpoints, unless otherwise noted. The term “about” as used in the disclosure of numerical ranges indicates that deviation from the stated value is acceptable to the extent that the deviation is the result of measurement variability and/or yields a product of the same or similar properties.


As used herein, “w/w %” and “wt %” means by weight as a percentage of the total weight.


In one aspect, a composition comprises pullulan, a setting system, water and a surfactant system. For example, a composition can contain from 75% to 95% by weight of pullulan, from 0.1% to 15% by weight of the setting system, and from 0.2 wt % to 3 wt % of the surfactant. For capsule compositions, wt % is based on total weight of contents of the capsule exclusive of any water present in the composition.


Pullulan


Pullulan (CAS number 9057-02-7; chemical synonyms 1,4-1,6-α-D-Gludan, 1,6-α-linked maltotriose) is a polysaccharide polymer consisting of maltotriose units. Three glucose units in maltotriose are connected by an α-1,4 glycosidic bond, whereas consecutive maltotriose units are connected to each other by an α-1,6 glycosidic bond. Maltotetraose units consisting of four 1,4-linked glucose molecules also occur, probably randomly, but are generally rare (about 6%). There is also evidence for a rare occurrence of branching points where poly-maltotriosyl side-chains are attached to the main chain by a 1,3-glycosidic bond.


Pullulan is generally produced from starch by the fungus Aureobasidium pullulans. Pullulan has good film forming properties and a particularly low oxygen permeability. Its existence was reported for the first time in 1938. Hayashibara Company started the commercial production in 1976.


In one embodiment, the pullulan has low amounts of mono-, di-, and oligosaccharides. Pullulan can be made free of mono-, di-, and oligosaccharides either through a post-manufacturing process step (e.g. precipitation of the mono-, di-, and oligosaccharides from a sample of a commercial pullulan grade in ethanol) or from its very production, by choosing appropriate fermentation conditions.


In one embodiment, the pullulan has an average molecular weight comprised between about 10 kDa to 1,000,000 kDa, preferably between 100 KDa and 750 KDa, more preferably between 200 KDa and 500 KDa. A 10 wt % aqueous solution of pullulan may have a viscosity of from 100 mm2/s to 180 mm2/s at 30° C.


In one embodiment, pullulan is manufactured using an organic fermentation process. In one such process the fermentation media contains calcium phosphate and magnesium chloride, This results in a capsule containing an excess of calcium and magnesium relative to monovalent cations such as potassium. In one embodiment, the capsules have a Ca2+ content of at least 200 mg/kg, or at least 300 mg/kg, or even at least 500 mg/kg. In another embodiment, the capsules have a Mg2+ content of at least 30 mg/kg, or at least 40 mg/kg, or even at least 50 mg/kg. In one embodiment, the ratio of K+/(Mg2++Ca2+) is less than 50, or less than 40, or less than 30, or even less than 20. A process for making pullulan using an organic manufacturing process is disclosed more fully in U.S. provisional patent application No. 62/485,855 filed Apr. 14, 2017, and filed as PCT/US2018/026063, on Apr. 9, 2016, both incorporated in their entireties by reference.


Setting System


The addition of a setting system, preferably based on polysaccharides, to pullulan solutions enables the adaptation of specific and desired gelling properties for the production of hard pullulan capsules by a conventional dipping process. In the dip molding process, the aqueous film forming pullulan solution from which the capsules are made remains on the mold pins after dipping, and does not flow down the pins. Otherwise the obtained film will not have the desired uniform thickness.


In one embodiment the setting system comprises a hydrocolloid or mixtures of hydrocolloids. Suitable hydrocolloids or mixtures thereof may be selected from natural seaweeds, natural seed gums, natural plant exudates, natural fruit extracts, biosynthetic gums, gelatines, and polysaccharides such as starch or cellulose derivatives.


In one embodiment, the polysaccharides are selected from the group comprising alginates, agar gum, guar gum, locust bean gum (carob), carrageenan, tara gum, gum arabic, ghatti gum, Khaya grandifolia gum, tragacanth gum, karaya gum, pectin, arabian (araban), xanthan, gellan, starch, Konjac mannan, galactomannan, funoran, and other exocellular polysaccharides. Preferred are exocellular polysaccharides.


Preferred exocellular polysaccharides for use in the present invention are selected from the group comprising xanthan, acetan, gellan, welan, rhamsan, furcelleran, succinoglycan, scleroglycan, schizophyllan, tamarind gum, curdlan, and dextran.


In a further preferred embodiment of the present invention the hydrocolloids of the setting system are kappa-carrageenan or gellan gum or combinations like xanthan with locust bean gum or xanthan with konjac mannan.


In one embodiment, the setting system is kappa-carrageenan with cations. In another embodiment, the setting system is gellan gum with cations. In another embodiment the setting system is agar with cations. These setting systems produce high gel strength at low concentrations and have good compatibility with pullulan.


As mentioned above, the setting system may contain a cation containing salt. The cation containing salt in the setting system serves to enhance the setting ability of the gelling agents. Preferably, the salt comprises cations such as K+, Li+, Na+, NH4+, Ca2+, or Mg2+, etc. The amount of cations in the capsule is from 0.01 to 1 wt %, preferably less than 3 wt %.


Surfactant


The pullulan containing compositions further comprise a surfactant that is selected from the group consisting of sucroglycerides, sugar fatty acid esters, and mixtures thereof.


Sucroglycerides are obtained by reacting sucrose with an edible fat or oil with or without the presence of a solvent. They consist of a mixture of mono- and di-esters of sucrose and fatty acids together with mono-, di- and triglycerides from the fat or oil. Exemplary fats and oils include lard oil, tallow, coconut, palm oil, and palmist oil. In one embodiment, the sucroglyceride is selected from the group consisting of coconut oil sucroglyceride, palm oil sucroglyceride, palmist oil sucroglyceride, soy oil sucroglyceride, rapeseed oil sucroglyceride, sunflower oil sucroglyceride, cottonseed oil sucroglyceride, palmist oil sucroglyceride, peanut oil sucroglyceride, olive oil sucroglyceride, canola oil sucroglyceride, castor oil sucroglyceride, corn oil sucroglyceride, flaxseed oil sucroglyceride, safflower oil sucroglyceride, and sesame oil sucroglyceride.


A preferred sucroglyceride is coconut oil sucroglyceride, or sucrose cocoate. Sucrose cocoate is a thick liquid that is pale yellow in color and derived from the fatty acids in coconut oil.


Sugar fatty acid esters are nonionic surfactants consisting of a sugar as the hydrophilic group and a fatty acid as lipophilic group. They are also referred to as sugar esters. In one embodiment, the only surfactants present in the composition are sugar fatty acid esters. Sugar ester fatty acids may be prepared from sugar and methyl and ethyl esters of food fatty acids by esterification in the presence of a catalyst or by extraction from the appropriate glyceride, such as from sucroglycerides.


Exemplary sugars that may be used as the head group include monosaccharides such as glucose, fructose, and galactose, disaccharides such as sucrose, maltose, trehalose and lactose, and trisaccharides such as raffinose.


Exemplary fatty acids that may be used as the lipophilic group include fatty acids having from 8 to 18 carbon atoms, including capyrlic acid (C8), decanoic acid (C10), lauric acid (C12), myristic acid (C14), palmitic acid (C16) and oleic acid (C18). The lipophilic group may be derived from the fatty acid esters from vegetable oils, such as those selected from the group consisting of coconut oil, palm oil, palmist oil, soy oil, rapeseed oil, sunflower oil, cottonseed oil, peanut oil, olive oil, canola oil, castor oil, corn oil, flaxseed oil, safflower oil, and sesame oil.


In a preferred embodiment, the vegetable oil is coconut oil.


In one embodiment, the sugar fatty acid ester is a sucrose fatty acid ester. Such sucrose esters may be formed from combining sucrose with particular fatty acids, and include sucrose laurate, sucrose stearate, sucrose erucate, sucrose oleate, sucrose palmitate, sucrose myristate, sucrose behenate, and sucrose ricenoleate. It is to be understood that such sucrose esters include the mono-, di-, tri- and poly-esters.


In one embodiment, the surfactant may also contain lecithin. The lecithin may be selected from any naturally occurring plant based source. in one embodiment, the lecithin is selected from the group consisting of soybean lecithin, peanut lecithin, cottonseed lecithin, sunflower lecithin, rapeseed lecithin, corn lecithin, and groundnut lecithin, In a preferred embodiment, the lecithin is sunflower lecithin,


The surfactant is present in an amount sufficient to aid in film formation n the mold pins during manufacturing. In one embodiment, the surfactant is present in an amount of at least 0.2 wt % of the capsule composition (exclusive of water content), In one embodiment, the amount of surfactant is present in an amount of from 0.2 wt % to 2 wt % of the capsule composition, or from 0.4 wt % to 1.5 wt % of the capsule composition, or from 0.5 wt % to 1 wt % of the capsule composition (exclusive of water).


Water


The capsules also generally comprise between 2 wt % and 20 wt %, preferably between about 5 wt % and 15 wt % of moisture or water over the total weight of the capsule. Unless otherwise indicated, when discussing capsule compositions, moisture and water are terms that can be used interchangeably. The amount of water present in the capsule compositions depends on both the materials present in the capsule, as well as the relative humidity of the environment in which the capsules are stored. (Accordingly, relative amounts of materials in the capsule compositions is determined relative to compositions not including water, since the amount of water is variable depending on the relative humidity of the environment.)


Typically, a capsule of the invention is dried to water content between about 10 wt % and 15 wt %. However, water content can be brought to lower % by e.g. further drying, capsule shell storage at low relative humidity or filling the capsule with hygroscopic substances.


Optional Materials


In addition to the pullulan, setting system, surfactant and water, the capsule compositions may contain a variety of other materials and processing aids, including those typically used in the manufacture of capsules.


Optionally, the capsule composition may further comprise at least one sequestering agent. Sequestering agents may be selected from the group consisting of ethylenediaminetetraacetic acid, acetic acid, boric acid, citric acid, edetic acid, gluconic acid, lactic acid, phosphoric acid, tartaric acid, or salts thereof, methaphosphates, clihydroxyethylglycine, lecithin or beta cyclodextrin and combinations thereof. Especially preferred is ethylenediaminetetraacetic acid or salts thereof or citric acid or salts thereof.


In the case that gellan is used as gelling agent, the compositions preferably contain a sequestering agent to improve the capsule solubility. The preferred sequestering agents are ethylenediaminetetraacetic acid or salts thereof and citric acid and salts thereof. The amount is preferably less than x wt % in the capsule compositions.


In another embodiment the capsule composition may additionally comprise pharmaceutically or food acceptable coloring agents in the range of from 0.01 wt % to 10 wt %. The coloring agents may be selected from the group consisting of azo-, guinophthalone-, triphenylmethane-, xanthene- or indigoid dyes, iron oxides or hydroxides, titanium dioxide or natural dyes or mixtures thereof. Examples are patent blue V, acid brilliant green BS, red 2G, azorubine, ponceau 4R, amaranth, D+C red 33, D+C red 22, D+C red 26, D+C red 28, D+C yellow 10, yellow 2 G. FD+C yellow 5, FD+C yellow 6, FD+C red 3, FD+C red 40, FD+C blue 1, FD+C blue 2, FD+C green 3, brilliant black BN, carbon black, iron oxide black, iron oxide red, iron oxide yellow, titanium dioxide, riboflavin, carotenes, anthocyanines, turmeric, cochineal extract, clorophyllin, canthaxanthin, caramel, or betanin.


In addition, the capsule compositions may optionally further include other minor components such as titanium dioxide and/or colorants such as mineral colorants, natural colorants, and tar colorants, anti-oxidants and the like.


In one embodiment, the pullulan composition optionally comprises one or more pharmaceutically or food acceptable plasticisers. In one embodiment, the one or more plasticizers are selected In the group of plasticizers typically used in the manufacture of hard capsule shells and in particular in the group consisting of: phthalic esters (e.g. dimethyl-, diethyl-, dibutyl-, diisopropyl- and dioctyl-phtalate); citric esters (e.g. Methyl-, tributyl-, acetyltriethyl- and acetyltributyl-citrate); phosphoric esters (e.g. triethyl-, tricresyl, triphenyl-phosphate); oils (e.g. purified mineral oils, ricin oil, corn oil, cotton oil); butyl stearate; dibutyl sebacate; dibutyl tartrate; diisobutyl adipate, glycerol monostearate; glycerol triacetate; tributyrin; oleic acid; stearic acid; cetylic acid; myristic acid; propylene glycol; glycerol; PEG 4000, PEG 6000, and mixtures thereof.


In one embodiment, the aqueous composition of the invention contains one or more pharmaceutically or food acceptable sweeteners and/or flavoring agents. Such sweeteners and flavoring agents are typically present in amounts from 0.01 wt % to 1 wt % of the pullulan composition.


Method for Making Capsules


In one aspect the capsules are manufactured by a conventional dip molding process as normally used in the production of conventional pullulan capsules. Consequently the use of a surfactant system comprising a sucroglyceride or sugar fatty acid ester enables hard pullulan capsules to be produced with the same equipment used for the production of conventional hard pullulan capsules in the same range of process conditions. Furthermore capsules produced from compositions of the present invention have the same dimensional specifications and allow the use of the existing filling machinery and do not require specific and new equipment for the filling process.


Capsules according to the present disclosure are typically made via a dip-molding process. Dip-molding processes for making acid-resistant two-piece hard capsules comprise the steps of:


a) providing an aqueous dipping composition comprising pullulan, a setting system, and a surfactant that is a sucroglyceride, a sugar fatty acid ester or mixture thereof;


b) dipping mold pins in the aqueous dipping composition;


c) extracting the mold pins from the dipping composition such that a film is formed over each of the mold pins;


d) drying the film to form a solid coating on the mold pins;


e) optionally applying an external lubricant to the solid coating on the mold pins;


f) removing the solid coating from the mold pins to provide capsule shells.


Steps (a) to (f) are typically to be performed in the order they are presented.


As described herein, “finished capsule shells” are those capsule shells for which step (f) has been completed.


In step (a) the aqueous dipping composition is prepared by combining water, pullulan, the setting system, and the sugar fatty acid ester. In one embodiment, the aqueous composition of the invention has a total amount of solids typically comprised between about 10% and 55% by weight, preferably between about 15% and 40%, more preferably between 20% and 30% by weight over the total weight of the composition. For amounts of materials in the aqueous dipping composition, wt % is given based on the total weight of the aqueous dipping composition including water.


In one embodiment, the aqueous composition of the invention has a total amount of solids so that the viscosity of the aqueous dipping composition at a temperature comprised between about 50° C. and 70° C. is between about 500 cPs and 5000 cPs, preferably between about 1000 to 3000 cps.


In one embodiment, the concentration of pullulan in the aqueous dipping composition is in a range of 10 to 60 wt %, preferably 10 to 50 wt %, more preferably 15 to 40 wt %, and most preferably 10 to 40 wt %.


The amount of the setting system is preferably in the range of 0.01 to 5% by weight and especially preferred 0.03 to 1.0% in the aqueous dipping composition. The preferred salt concentration in the aqueous dipping concentration is less than 2 wt %.


In another embodiment of the present invention, the amount of the optional sequestering agent is less than 5% by weight, preferably less than 3%, more preferably 0.01% to 3% by weight, even more preferably 0.5% to 2% by weight especially 0.01 to 1% by weight of the aqueous dipping composition.


In addition, the aqueous dipping compositions may optionally further include other minor components such as titanium dioxide and/or colorants such as mineral colorants, natural colorants, and tar colorants, anti-oxidants and the like. In one embodiment, the coloring agents, or mixtures thereof are present in an amount ranging from about 0 to about 5% by weight, e.g., from about 0 to about 2.5% by weight, and from about 0 to about 1.5% by weight over the total weight of the aqueous dipping composition.


In step (b) mold pins are dipped in the aqueous dipping composition. The relative temperatures of the aqueous dipping composition and mold pins are chosen to result in film formation on the mold pins once the mold pins are dipped into the aqueous composition. In this embodiment the aqueous composition at the time the mold pins are dipped is kept at a temperature of from 45° C. to 55° C., preferably from 50° C. to 65° C. The temperature range of the pins is 25-35° C., meaning that this is the mold pin temperature when mold pins are dipped.


In step (c), the mold pins are extracted from the aqueous dipping composition such that a film is formed over each of the mold pins. After being withdrawn from the aqueous dipping composition, the mold pins can be turned from a “top-down” dipping position to a “top-up” drying position according to conventional capsule clip molding processes. In this step the pins are rotated about a horizontal axis of about 180′ with respect to the dipping position of step (c).


In step (d), the film on the mold pins is dried. The purpose of the drying step (d) is to reduce the water content (also referred to herein as “moisture”) in the capsule shells on the mold pins. In one embodiment, drying occurs at a temperature above the gelling temperature of the aqueous dipping composition so as to obtain molded capsule shells on the pins. The drying step is preferably carried out at a temperature of less than 65° C., preferably less than 60° C., even more preferably from 25° C. to 45° C. Step (d) is typically carried out for a period of time from 30 to 60 minutes, preferably not exceeding the above identified temperatures. Generally, the water content in the molded capsule shells is reduced from around 80% to around 10 to 15% by weight, based on the total weight of the molded capsule shells (measured at room conditions).


In step (f) the solid coating is removed from the mold pins to provide capsule shells. The solid coating may be removed using any conventional manufacturing technique.


The solid coating in step (e) and the mold pins may be lubricated. In the case of the solid coating, the lubricant enhances gliding of the capsule shells to facilitate filling and closing. With respect to the mold pins, the lubricant facilitates removal of the capsule shells. In yet another aspect of the invention, the lubricant used for the external application to the solid coatings and/or to the mold pins is selected from a mixture of lecithin and a vegetable oil. The lecithin may be selected from any naturally occurring plant based source. In one embodiment, the lecithin is selected from the group consisting of soybean lecithin, peanut lecithin, cottonseed lecithin, Sunflower lecithin, rapeseed lecithin, corn lecithin, and groundnut lecithin. In a preferred embodiment, the lecithin is sunflower lecithin.


The vegetable oil may be selected from any naturally occurring vegetable oil. In one embodiment, the vegetable oil is selected from the group consisting of coconut oil, palm oil, palmist oil, soy oil, rapeseed oil, sunflower oil, cottonseed oil, peanut oil, olive oil, canola oil, castor oil, corn oil, flaxseed oil, safflower oil, and sesame oil. In a preferred embodiment, the vegetable oil is coconut oil.


The relative amount of lecithin to vegetable oil ranges from 90/10 lecithin/vegetable oil to 50/50 lecithin/vegetable oil.


In one embodiment, the lubricant comprises a mixture of coconut oil and sunflower lecithin. The mixture of sunflower lecithin and coconut oil is at a ratio of between 90/10 to 50/50 sunflower lecithin/coconut oil, more preferably between 80/20 and 60/40 sunflower lecithin/coconut oil.


In another embodiment, the lubricant comprises a sucroglyceride or sugar fatty acid ester. In one embodiment, the lubricant is a sucroglyceride, preferably sucrose cocoate. In another embodiment, the lubricant comprises a sugar fatty acid ester derived from coconut oil. The lubricant may also optionally comprise lecithin in addition to the sucroglyceride or sugar fatty acid ester in a ratio of from 1/99 to 50/50 lecithin/sucrose glyceride or lecithin/sugar fatty acid ester.


In one embodiment, the lubricant comprises a mixture of sucrose cocoate and sunflower lecithin in a ratio of from 1/99 to 50/50 sunflower lecithin/sucrose cocoate. In one embodiment, the lubricant consists essentially of a mixture of sucrose cocoate and sunflower lecithin in a ratio of from 1/99 to 50/50 sunflower lecithin/sucrose cocoate.


The molded capsule shells mentioned to above, generally refer to both bodies and caps, depending on the shape of the mold pin. Thus, after step (e) the dried capsule shells on the dipping pins can be processed according to conventional steps. This means that in general after step (e), the capsule shells (bodies and caps) are stripped from the pins. This step can be followed by cutting the stripped shells to a desired length.


Methods of Use


The capsule compositions are suitable for use in pharmaceutical, veterinary, food, cosmetic or other products.


Drugs (i.e. medicaments) suitable for use in the capsules described herein may take any form and be for any treatment of a human or animal subject. This Includes not only pharmaceutical compounds but also dietary supplements such as vitamins, minerals and the like. The drug may be in a state selected from solid or liquid, preferably solid, at room temperature and atmospheric pressure, and comprises one or more active compounds. The medicament may be solid and in the form of spray dried dispersions, pellets, granules and the like.


Suitable compounds (and generally encompassed by the term “medicament” as used herein) for delivery according to the disclosure include, but are not limited to, particulate, powder, waxy, liquid, and/or pellet forms of the following:


a) pharmaceuticals (also called pharmaceutical actives) such as betamethasone, thioctic acid, sotalol, salbutamol, norfenefrine, silymahn, dihydroergotamine, buflomedil, etofibrate, indomethacin, oxazepam, acetyldigitoxins, piroxicam, halopehdol, isosorbide mononitrate, amithptyfine, diclofenac, nifedipine, verapamil, pyritinol, nitrendipine, doxy-cycline, bromhexine, methylprednisolone, clonidine, fenofibrate, allopurinol, pirenzepine, levothyroxine, tamoxifen, metildigoxin, o-(B-hydroxyethyl)-rutoside, propicillin, aciclovir-mononitrate, paracetamolol, naftidrofuryl, pentoxifylline, propafenone, acebutolol, 1-thyroxin, tramadol, bromocriptine, loperamide, ketofinen, fenoterol, cadobesilate, propranolol, minocycline, nicergoline, ambroxol, metoprolol, B-sitosterin, enalaprilhydrogenmaleate, bezafibrate, isosorbide dinitrate, gallopamil, xantinolnicotinate, digitoxin, flunitrazepam, bencyclane, depanthenol, pindolol, lorazepam, diltiazem, piracetam, phenoxymethylpenicillin, furosemide, bromazepam, flunarizine, erythromycin, metoclopramide, acemetacin, ranitidine, biperiden, metamizol, doxepin, dipotassiumchlorazepat, tetrazepam, estramustinephosphate, terbutaline, captopril, maprotiline, prazosin, atenolol, glibenclamid, cefaclor, etilefrin, cimetidine, theophylline, hydromorphone, ibuprofen, primidone, clobazam, oxaceprol, medroxyprogesterone, flecainide, Mg pyhdoxal-5-phosphateglutaminate, hymechromone, etofyllineclofibrate, vincamine, cinnarizine, diazepam, ketoprofen, flupentixol, molsidomine, glibornuhde, dimethindene, melperone, soquinolol, dihydrocodeine, clomethiazole, clemastine, glisoxepid, kallidino-genase, oxyfedhne, baclofen, carboxymethylcystsin, thioredoxin, betahistine, 1-tryptophan, myrtol, bromelain, prenylamine, salazosulfapyridine, astemizole, sulpiride, benzerazid, dibenzepin, acetylsalicylic acid, miconazole, nystatin, ketoconazole, sodium picosulfate, colestyramate, gemfibrozil, rifampin, fluocortolone, mexiletine, amoxicillin, terfenadine, mucopolysaccharidpolysulfuric acid, triazolam, mianserin, tiaprofensaure, ameziniummethylsulfate, mefloquine, probucol, quinidine, carbamazepine, Mg-1-aspartate, penbutolol, piretanide, amitriptyline, caproteron, sodium valproinate, mebeverine, bisacodyl, 5-amino-salicyclic acid, dihydralazine, magaldrate, phenprocoumon, amantadine, naproxen, carteolol, famotidine, methyldopa, auranofine, estriol, nadolol, levomepromazine, doxorubicin, medofenoxat, azathioprine, flutamide, norfloxacin, fendiline, prajmaliumbitartrate, aescin acromycin, anipamil, benzocaine, [beta]-carotene, cloramphenicol, chlorodiazepoxid, chlormadinoneacetate, chlorothiazide, cinnarizine, clonazepam, codeine, dexamethasone, dicumarol, digoxin, drotaverine, gramicidine, griseofulvin, hexobarbital hydrochlorothiazide, hydrocortisone, hydroflumethiazide, ketoprofen, lonetil, medazepam, mefruside, methandrostenolone, suifaperine, nalidixic acid, nitrazepam, nitrofurantoin, estradiol, papaverine, phenacetin, phenobarbital, phenylbutazone, phenytoin, prednisone, reserpine, spironolactine, streptomycin, sulfamethizole, sulfamethazine, sulfamethoxoazole, sulfamethoxydiazinon, sulfathiazole, sulfisoxazole, testosterone, tolazamide, tolbutamide, trimethoprim, tyrothricin, antacids, reflux suppressants, antiflatulents, antidopaminergics, proton pump inhibitors, H2-receptor antagonists, cytoprotectants, prostaglandin analogues, Laxatives, antispasmodics, antidiarrhoeals, bile acid sequestrants, opioids, beta-receptor blockers, calcium channel blockers, diuretics, cardiac glycosides, antiarrhythmics, nitrates, antianginals, vasoconstrictors, vasodilators, ACE inhibitors, angiotensin receptor blockers, alpha blockers, anticoagulants, heparin, antiplatelet drugs, fibrinolytic, anti-hemophilic factor, haemostatic drugs, hypolipidaemic agents, statins, hypnotics, anaesthetics, antipsychotics, antidepressants (including tricyclic antidepressants, monoamine oxidase inhibitors, lithium salts, selective serotonin reuptake inhibitors), anti-emetics, anticonvulsants, antiepileptics, anxiolytics, barbiturates, movement disorder drugs, stimulants (including amphetamines), benzodiazepine, cyclopyrrolone, dopamine antagonists, antihistamines, cholinergics, anticholinergics, emetics, cannabinoids, 5-HT antagonists, analgesics, muscle relaxants, antibiotics, sulfa drugs, aminoglycosides, fluoroquinolones, bronchodilators, NSAIDs, anti-allergy drugs, antitussives, mucolytics, decongestants, corticosteroids, beta-receptor antagonists, anticholinergics, steroids, androgens, antian-drogens, gonadotropin, corticosterolds, growth hormones, insulin, antidiabetic drugs (including sulfonylurea, biguanide/metformin, and thiazolidinedione), thyroid hormones, antithyroid drugs, calcitonin, diphosponate, vasopressin analogs, contraceptives, follicle stimulating hormone, luteinising hormone, gonadotropin release inhibitor, progestogen, dopamine agonists, oestrogen, prostaglandin, gonadorelin, clomiphene, tamoxifen, diethylstilbestrol antimalarials, anthelmintics, amoebicides, antivirals, antiprotozoals, vaccines, immunoglobulin, immunosuppressants, interferon, monoclonal antibodies, and mixtures thereof;


b) vitamins, e.g., fat-soluble vitamins such as vitamins A, D, E, and K, and water soluble vitamins such as vitamin C, biotin, folate, niacin, pantothenic acid, riboflavin, thiamin, vitamin B6, vitamin B12, and mixtures thereof;


c) minerals, such as calcium, chromium, copper, fluoride, iodine, iron, magnesium, manganese, molybdenum, phosphorus, potassium, selenium, sodium (including sodium chloride), zinc, and mixtures thereof;


d) dietary supplements such as herbs or other botanicals, amino acids, and substances such as enzymes, organ tissues, glandulars, and metabolites, as well as concentrates, metabolites, constituents, extracts of dietary ingredients, oils such as krill oil and mixtures thereof;


e) homoeopathic ingredients such as those listed in the Homeopathic Pharmacopoeia of the United States Revision Service (HPRS), and mixtures thereof. It must be recognized, of course, that the HPRS is periodically updated and that the present invention Includes homeopathic ingredients that may be added to the HPRS;


f) probiotics and yeast, such as bacteria selected from the group consisting of Lactobacillus (Döderlein's bacilli) such as Lactobacillus crispatus, Lactobacillus jensinii, Lactobacillus johnsonii, Lactobacillus gasseri, Enterococcus feecium, or fungi selected from the group of Saccharomycetales such Saccharomyces boulardii.


g) hormones, such as estrogen (i.e. a natural estrogen or a synthetic compound that mimics the physiological effect of natural estrogens) including, without limitation, estradiol (17-estradiol), estridiol acetate, estradiol benzoate, estridiol cypionate, estridiol decanoate, estradiol diacetate, estradiol heptanoate, estradiol valerate, 17a-estradiol, estriol, estriol succinate, estrone, estrone acetate, estrone sulfate, estropipate (piperazine estrone sulfate), ethynylestradiol (17a-ethynylestradiol, ethinylestradiol, ethinyl estradiol, ethynyl estradiol), ethynylestradiol 3-acetate, ethynylestradiol 3-benzoate, mestranol, quinestrol, nitrated estrogen derivatives or combinations thereof; or progestin (i.e. natural or synthetic compounds that possesses progestational activity including, without limitation, nortestosterone, ethynyltestosterone, deacetylnorgestimate, hydroxyprogesterone, 19-norprogesterone, 3P-hydroxydesogestrel, 3-ketodesogestrel (etonogestrel), acetoxypregnenolone, algestone acetophenide, allylestrenol, amgestone, anagestone acetate, chlormadinone, chlormadinone acetate, cyproterone, cyproterone acetate, clemegestone, desogestrel, dienogest, dihydrogesterone, dimethisterone, drospirenone, dydrogesterone, ethisterone (pregneninolone. 17a-ethynyltestosterone), ethynodiol diacetate, fluorogestone acetate, gestrinone, gestadene, gestodene, gestonorone, gestrinone, hydroxymethylprogesterone, hydroxymethylprogesterone acetate, hydroxyprogesterone, hydroxyprogesterone acetate, hydroxyprogesterone caproate, levonorgestrel (1-norgestrol), lynestrenol (lynoestrenol), mecirogestone, medrogestone, medroxyprogesterone, medroxyprogesterone acetate, megestrol, megestrol acetate, melengestrol, melengestrol acetate, nestorone, nomegestrol, norelgestromin, norethindrone (norethisterone) (19-nor-17a-ethynyltestosterone), norethindrone acetate (norethisterone acetate), norethynodrel, norgestimate, norgestrel (d-norgestrel and dl-norgestrel), norgestrienone, normethisterone, progesterone, promegestone, quingestanol, tanaproget, tibolone, trimegestone, or combinations thereof.


Once filled, the capsules can be made tamper-proof by using any conventional technique in the field of hard capsules to make the joint permanent. Banding or sealing are suitable techniques. Sealing is a technique well known in the field of hard shell capsules. Various alternative techniques are currently used for this purpose. A suitable procedure is disclosed for example in U.S. Pat. No. 4,539,000 and U.S. Pat. No. 4,656,066,


In yet another embodiment of the invention, the compositions comprising pullulan, a setting system, water and a sucroglyceride or sugar fatty acid ester may be used to form films. Such films may be used for a variety of other purposes, such as for wrapping food, or for forming aspics or jellies.


It should be understood that the embodiments described herein are not limited thereto. Other embodiments of the present disclosure will be apparent to those skilled in the art from consideration of the specification and practice of the disclosed embodiments. The following examples should be considered as exemplary only, with a true scope and spirit of the present disclosure being indicated by the following claims.


EXAMPLE 1

Capsules were made as follows. An aqueous dipping solution was prepared by first adding 443 liters of an aqueous solution of pullulan (22 wt % pullulan) to a melt tank and heating the solution to 65° C. 1.65 kg potassium chloride was mixed in 3 liters of 65° C. water, and the resulting solution was added to the melt tank and stirred. 460.59 of kappa carrageenan (available from CP Kelco, Denmark), was added to the melt tank as follows. An aliquot of 115.13g of carrageenan was mixed with 3 liters of cold water and then added to the melt tank and stirred. Three additional aliquots of 115.13g of carrageenan were similarly prepared and added to the melt tank. The solution was then mixed at 50 RPM for 60 minutes, and then placed under vacuum and mixed for an additional 60 minutes. The solution was then mixed for 60 minutes at 33 RPM under vacuum. 160 liters of the solution in the melt tank were then dispensed into a transfer tank. 1600 g of a 12.5 wt % aqueous solution of sucrose cocoate (ESAC 80 available from Tensac, Argentina) was then added to the transfer tank and stirred to form the clipping composition. Water was then added to achieve a viscosity of 800 cps.


Capsules were prepared using dip molding equipment. The aqueous dipping composition was heated to 65° C. The pins were maintained at 30° C.


The mold pins were lubricated with a mixture of sunflower lecithin and Coconut oil at a ratio of 70/30 sunflower lecithin/coconut oil.


The resulting capsules had the following composition


Excluding water:
















Ingredient
Wt %



















Pullulan
97.43



Potassium chloride
1.61



Kappa Carrageenan
0.45



Sucrose cocoate
0.52










Including water:
















Ingredient
Wt %



















Pullulan
85.73



Potassium chloride
1.41



Kappa Carrageenan
0.39



Sucrose cocoate
0.45



Water
12.01










EXAMPLE 2

In this example, capsules produced from organic pullulan made according to Example 1 (Capsule A) and Plantcapsi® capsules from Capsugel, Greenwood, S.C., (Capsule B) were analyzed for Mg2+ and K+ content using the standard protocol SM3111B using Flame Atomic Absorption Spectroscopy. In addition, Ca2+ content in these capsule was also measured using the standard protocol SM3111D using Flame Atomic Absorption Spectroscopy. Each capsule batch was analyzed in triplicate. From this analysis it was determined that the concentration of both Mg2+ and Ca2+ is higher in Capsule A than Capsule B. In addition, Capsule A capsules have a lower ratio of monovalent cation (K+) to divalent cations (Mg2+ and Ca2+),









TABLE 1







Results of Metal Analysis of Capsules










Capsule A
Capsule B
















Mg2+ (mg/kg)
Ca2+ (mg/kg)
K+ (mg/kg)





K


+



(


Mg

2
+


+

Ca

2
+



)





Mg2+ (mg/kg)
Ca2+ (mg/kg)
K+ (mg/kg)





K


+



(


Mg

2
+


+

Ca

2
+



)























Replicate 1
58.6
704
7920
10.4
18.2
104
7500
61.4


Replicate 2
58.2
680
7740
10.5
18.4
101
7410
62.1


Replicate 3
59.4
680
7590
10.3
19
98.3
7560
64.5


Mean ±
58.7 ± 0.6
688 ± 13.9
7750 ± 165
10.4 ± 0.1
18.5 ± 0.4
101 ± 2.9
7490 ± 75
62.6 ± 1.6


St. Dev





Values expressed in mg metal per kilogram capsule





Claims
  • 1. A capsule comprising: a) pullulan in an amount of at least 70 wt % of said capsule;b) a setting system in an amount of at least 0.01 wt % of said capsule;c) a surfactant comprising a sucroglyceride or a sugar fatty acid ester or mixture thereof, wherein said sucroglyceride or said sugar fatty acid ester comprises a lipophilic group derived from the fatty acid esters of a vegetable oil selected from the group consisting of coconut oil, palm oil, palmist oil, soy oil, rapeseed oil, sunflower oil, cottonseed oil, peanut oil, olive oil, canola oil, castor oil, corn oil, flaxseed oil, safflower oil, and sesame oil, the sucroglycerides, sugar fatty acid esters, and mixtures thereof are present in an amount of greater than 0.2 wt % of said capsule;wherein said wt % amounts are exclusive of water present in the capsule.
  • 2. A capsule consisting essentially of: a) pullulan in an amount of at least 70 wt % of said capsule;b) a setting system in an amount of at least 0.01 wt % of said capsule;c) a surfactant selected from the group consisting of sucroglycerides, sugar fatty acid esters, and mixtures thereof in an amount of at least 0.2 wt % of said capsule;wherein said wt % amounts are exclusive of water present in the capsule.
  • 3. The capsule of claim 1 wherein said pullulan is manufactured using an organic fermentation process.
  • 4. A capsule comprising: a) pullulan in an amount of at least 70 wt % of said capsule;b) a setting system in an amount of at least 0.01 wt % of said capsule; andc) a surfactant comprising a sugar fatty acid ester, wherein said sugar fatty acid comprises a sugar head group selected from the group consisting of glucose, fructose, galactose, sucrose, maltose, trehalose, lactose, and raffinose;wherein said wt % amounts are exclusive of water present in the capsule.
  • 5. The capsule of claim 1 wherein said surfactant is a sucrose fatty acid ester.
  • 6. The capsule of claim 1 wherein said surfactant is a sucroglyceride.
  • 7. The capsule of claim 5 wherein said surfactant is derived from the fatty acids of coconut oil.
  • 8. A capsule comprising: a) pullulan in an amount of at least 70 wt % of said capsule;b) a setting system in an amount of at least 0.01 wt % of said capsule;c) a surfactant comprising sucrose cocoate;wherein said wt % amounts are exclusive of water present in the capsule.
  • 9. The capsule of claim 1 wherein said surfactant is present in an amount of from 0.2 wt % to 2 wt % of the capsule composition exclusive of water.
  • 10. The capsule according to claim 1, further comprising at least one sequestering agent.
  • 11. The capsule according to claim 1, further comprising plasticizers or/and flavoring agents.
  • 12. The capsule according to claim 1, further comprising coloring agents in a range from about 0% to 10% based upon the weight of the composition.
  • 13. The capsule according to claim 1, wherein the capsule comprises a coating.
  • 14. A caplet encapsulated in a capsule according to claim 1.
  • 15. A method for manufacturing the capsule of claim 1, comprising: a) providing an aqueous dipping composition comprising pullulan, said setting system, and said surfactant;b) dipping mold pins in the aqueous dipping composition;c) extracting the mold pins from the aqueous dipping composition such that a film is formed over each of the mold pins;d) drying the film to form a solid coating on the mold pins;e) removing the solid coating from the mold pins to provide capsule shells.
  • 16. The method of claim 15 wherein said mold pins are lubricated with a mixture of lecithin and a vegetable oil.
  • 17. The method of claim 15 wherein said solid coating is lubricated with a mixture of lecithin and a vegetable oil.
  • 18. The method of claim 16 wherein said lecithin is soybean lecithin, peanut lecithin, cottonseed lecithin, sunflower lecithin, rapeseed lecithin, corn lecithin, groundnut lecithin, or any mixture thereof.
  • 19. The method of claim 16 wherein said vegetable oil is coconut oil, palm oil, palmist oil, soy oil, rapeseed oil, sunflower oil, cottonseed oil, peanut oil, olive oil, canola oil, castor oil, corn oil, flaxseed oil, safflower oil, sesame oil, or any mixture thereof.
  • 20. The method of claim 15 wherein the mold pins are lubricated with a mixture of coconut oil and sunflower lecithin.
  • 21. The method of claim 15 wherein the mold pins are lubricated with a sucroglyceride or a mixture of a sucroglyceride and lecithin.
  • 22. A capsule comprising: a) pullulan in an amount of at least 70 wt % of said capsule;b) a setting system in an amount of at least 0.01 wt % of said capsule;c) a surfactant comprising a sucroglyceride or a sugar fatty acid ester or mixture thereof, wherein said sucroglyceride or said sugar fatty acid ester comprises a lipophilic group derived from the fatty acid esters of a vegetable oil selected from the group consisting of coconut oil, palm oil, palmist oil, soy oil, rapeseed oil, sunflower oil, cottonseed oil, peanut oil, olive oil, canola oil, castor oil, corn oil, flaxseed oil, safflower oil, and sesame oil;wherein said wt % amounts are exclusive of water present in the capsule; andwherein the capsules have a Ca2+content of at least 200 mg/kg.
  • 23. The capsule of claim 22 wherein the capsules further comprise Mg2+with a Mg2+content of at least 30 mg/kg.
  • 24. The capsule of claim 22 wherein the capsules further comprise K+and Mg2+with a ratio of K+/(Mg2++Ca2+) of less than 50.
CROSS REFERENCE TO RELATED APPLICATIONS

This is the U.S. National Stage of International Application No. PCT/IB2018/000448, filed Apr. 10, 2018, which was published in English under PCT Article 21(2), which in turn claims the benefit of U.S. Provisional Application No. 62/485,854, filed Apr. 14, 2017, each of which is herein incorporated by reference in its entirety.

PCT Information
Filing Document Filing Date Country Kind
PCT/IB2018/000448 4/10/2018 WO
Publishing Document Publishing Date Country Kind
WO2018/189584 10/18/2018 WO A
US Referenced Citations (207)
Number Name Date Kind
3654088 Coker et al. Apr 1972 A
3779972 Bolles Dec 1973 A
3784390 Hijiya Jan 1974 A
3827937 Kato et al. Aug 1974 A
3870537 Hijiya et al. Mar 1975 A
3871892 Hijiya et al. Mar 1975 A
3872228 Hijiya et al. Mar 1975 A
3873333 Hijiya et al. Mar 1975 A
3875308 Kato et al. Apr 1975 A
3888809 Nakashio et al. Jun 1975 A
3912591 Kato et al. Oct 1975 A
3931146 Kato et al. Jan 1976 A
3932192 Nakashio et al. Jan 1976 A
3936347 Nomura Feb 1976 A
3954724 Nakashio et al. May 1976 A
3959009 Kato et al. May 1976 A
3960685 Sano et al. Jun 1976 A
3962155 Usamoto et al. Jun 1976 A
3972997 Nakashio et al. Aug 1976 A
3976605 Matsunaga et al. Aug 1976 A
3976819 Mori et al. Aug 1976 A
3992496 Matsunaga et al. Nov 1976 A
3993840 Tsuji et al. Nov 1976 A
3997703 Nakashio et al. Dec 1976 A
4004977 Kato et al. Jan 1977 A
4018233 Miyake Apr 1977 A
4029616 Nakashio et al. Jun 1977 A
4029886 Nakashio et al. Jun 1977 A
4032403 Sakai et al. Jun 1977 A
4045204 Matsunaga et al. Aug 1977 A
4045388 Matsunaga et al. Aug 1977 A
4067141 Matsunaga et al. Jan 1978 A
4152170 Nagase et al. May 1979 A
4167623 Fujita et al. Sep 1979 A
4174440 Fujita et al. Nov 1979 A
4186024 Fujimoto et al. Jan 1980 A
4205218 Fukami et al. May 1980 A
4247642 Hirohara et al. Jan 1981 A
4306059 Yokobayashi et al. Dec 1981 A
4338398 Yoneyama Jul 1982 A
4370472 Igarashi et al. Jan 1983 A
4372883 Matuhashi et al. Feb 1983 A
4474756 Mitsuhashi et al. Oct 1984 A
4562020 Hijiya et al. Dec 1985 A
4579259 Hirao et al. Apr 1986 A
4610891 Miyamoto et al. Sep 1986 A
4618664 Ohnishi Oct 1986 A
4628028 Katkocin et al. Dec 1986 A
4650757 David et al. Mar 1987 A
4659569 Mitsuhashi et al. Apr 1987 A
4683298 Yalpani Jul 1987 A
4745042 Sasago et al. May 1988 A
4758660 Takeuchi et al. Jul 1988 A
4777065 Hirao et al. Oct 1988 A
4816445 Mitsuhashi et al. Mar 1989 A
4822601 Goode Apr 1989 A
4824938 Koyama et al. Apr 1989 A
4889728 Maeda et al. Dec 1989 A
4927636 Hijiya et al. May 1990 A
4962026 Keng Oct 1990 A
4965347 Misaki et al. Oct 1990 A
5019514 Bock et al. May 1991 A
5073628 Matsuhashi et al. Dec 1991 A
5077336 Nakashita et al. Dec 1991 A
5082803 Sumita Jan 1992 A
5100877 Mori et al. Mar 1992 A
5143646 Nochumson et al. Sep 1992 A
5147795 Ara et al. Sep 1992 A
5147796 Ara et al. Sep 1992 A
5264223 Yamamoto et al. Nov 1993 A
5268460 Thorne et al. Dec 1993 A
5281527 Tachibana et al. Jan 1994 A
5316691 Sone et al. May 1994 A
5362779 Kitayama et al. Nov 1994 A
5366879 Kitahata et al. Nov 1994 A
5411945 Ozaki et al. May 1995 A
5518902 Ozaki et al. May 1996 A
5552166 Harada et al. Sep 1996 A
5583039 Park et al. Dec 1996 A
5583244 Uchida et al. Dec 1996 A
5631221 Kohno et al. May 1997 A
5709801 Murofushi et al. Jan 1998 A
5756123 Yamamoto et al. May 1998 A
5837673 Tsujihara et al. Nov 1998 A
5871088 Tanabe Feb 1999 A
5874401 Sanou et al. Feb 1999 A
6242224 Nakano et al. Jun 2001 B1
6368635 Akiyama et al. Apr 2002 B1
6387666 Thorne et al. May 2002 B1
6410050 Yang Jun 2002 B1
6449925 Otsu et al. Sep 2002 B1
6596298 Leung et al. Jul 2003 B2
6610810 Phillips et al. Aug 2003 B2
6887307 Scott May 2005 B1
6916796 Wolf Jul 2005 B2
6972189 Han et al. Dec 2005 B2
7098013 Kubota et al. Aug 2006 B2
7101533 Matsuo et al. Sep 2006 B2
7179891 Mayumi et al. Feb 2007 B2
7186824 Aga et al. Mar 2007 B2
7259197 Mitsui et al. Aug 2007 B2
7237718 Scott et al. Sep 2007 B2
7265168 Mitsui et al. Sep 2007 B2
7265191 Kinoshita et al. Sep 2007 B2
7267718 Scott et al. Sep 2007 B2
7396543 Matsunaga et al. Jul 2008 B2
7414038 Kinugasa et al. Aug 2008 B2
7417135 Bardowski et al. Aug 2008 B2
7445921 Oura et al. Nov 2008 B2
7638241 Lee et al. Dec 2009 B2
7749538 Sugimoto et al. Jul 2010 B2
7815935 Li et al. Oct 2010 B2
7815952 Inoue et al. Oct 2010 B2
7856989 Karies et al. Dec 2010 B2
8017143 Shin et al. Sep 2011 B2
8105625 Rajewski et al. Jan 2012 B2
8168778 Nishimoto et al. May 2012 B2
8192761 Ochiai et al. Jun 2012 B2
8324375 Watanabe et al. Dec 2012 B2
8361386 Davis et al. Jan 2013 B2
8536111 Watanabe et al. Sep 2013 B2
8632652 Lee et al. Jan 2014 B2
8791232 Dekx et al. Jul 2014 B2
8821934 Sugimoto et al. Sep 2014 B2
8900629 Rajewski et al. Dec 2014 B2
8951996 Giliyar et al. Feb 2015 B2
8986735 Schobel et al. Mar 2015 B2
9073294 Kumar et al. Jul 2015 B2
20020009522 Hirai et al. Jan 2002 A1
20020131990 Barkalow et al. Sep 2002 A1
20030017209 Parikh et al. Jan 2003 A1
20030054499 Han et al. Mar 2003 A1
20030059479 Miyake Mar 2003 A1
20030087002 Fouache et al. May 2003 A1
20030104048 Patel Jun 2003 A1
20030108593 Oku et al. Jun 2003 A1
20030134409 Mallouk et al. Jul 2003 A1
20040013723 Parikh et al. Jan 2004 A1
20040126330 Awamura et al. Jul 2004 A1
20040131661 Auffret et al. Jul 2004 A1
20040236017 Bruzzano et al. Nov 2004 A1
20050019448 Engelhardt Jan 2005 A1
20050031853 Scott et al. Feb 2005 A1
20050065030 Oku et al. Mar 2005 A1
20050202083 Kumar et al. Sep 2005 A1
20050249676 Scott et al. Nov 2005 A1
20060011118 Hayashi et al. Jan 2006 A1
20060147542 Ono et al. Jul 2006 A1
20060159752 Jain et al. Jul 2006 A1
20060223140 Oura et al. Oct 2006 A1
20060233875 Mathur et al. Oct 2006 A1
20060257482 Kumar et al. Nov 2006 A1
20070042035 Momoi Feb 2007 A1
20070042970 Sunamoto et al. Feb 2007 A1
20070087939 Cade Apr 2007 A1
20070092600 Miyai et al. Apr 2007 A1
20070099996 Isloor May 2007 A1
20070218189 Oku et al. Sep 2007 A1
20070219250 Singh et al. Sep 2007 A1
20070258941 Pfister Nov 2007 A1
20070292481 Hoffman et al. Dec 2007 A1
20080008750 Tochio et al. Jan 2008 A1
20080038432 Hoffman et al. Feb 2008 A1
20080223395 Maillefer et al. Sep 2008 A1
20080248102 Rajewski et al. Oct 2008 A1
20080274187 Cao Nov 2008 A1
20090048188 Matsuo et al. Feb 2009 A1
20090110728 Rastogi et al. Apr 2009 A1
20090274636 Shinohara et al. Nov 2009 A1
20090291138 Watanabe et al. Nov 2009 A1
20100003590 Park et al. Jan 2010 A1
20100093875 Matsui et al. Apr 2010 A1
20100166690 Masachika Jul 2010 A1
20110015309 Brecker et al. Jan 2011 A1
20110020757 Kawauchi et al. Jan 2011 A1
20110086070 Talwar et al. Apr 2011 A1
20110091814 Endo Apr 2011 A1
20110139164 Mua et al. Jun 2011 A1
20110177137 Chauhan et al. Jul 2011 A1
20110177297 Jung et al. Jul 2011 A1
20110206729 Akiyoshi et al. Aug 2011 A1
20110207686 Lecommandoux et al. Aug 2011 A1
20110236935 Mikkelsen et al. Sep 2011 A1
20110244047 Asari et al. Oct 2011 A1
20110268797 Cifter et al. Nov 2011 A1
20110292566 Tan et al. Dec 2011 A1
20120037039 Nieto Feb 2012 A1
20130005831 Rajewski et al. Jan 2013 A1
20130160779 Chida et al. Jun 2013 A1
20130195941 Shibuya et al. Aug 2013 A1
20130244082 Lee et al. Sep 2013 A1
20130287842 Cade et al. Oct 2013 A1
20130288932 Mackenzie et al. Oct 2013 A1
20130323307 Jeon et al. Dec 2013 A1
20130344147 Kainose et al. Dec 2013 A1
20140010882 Matsuda et al. Jan 2014 A1
20140170213 Kim et al. Jun 2014 A1
20140178555 Fujimoto et al. Jun 2014 A1
20140187538 Bogo et al. Jul 2014 A1
20150111862 Podolski Apr 2015 A1
20150112250 Kwon Apr 2015 A1
20150209275 Choonara et al. Jul 2015 A1
20150274605 Waldron et al. Oct 2015 A1
20160038729 Kato Feb 2016 A1
20180256506 Cade et al. Sep 2018 A1
20190046454 Cade et al. Dec 2019 A1
20200291439 Breit et al. Sep 2020 A1
Foreign Referenced Citations (409)
Number Date Country
2018251256 Nov 2019 AU
2018253392 Nov 2019 AU
112019021396 Apr 2020 BR
112019021391 May 2020 BR
1037887 Sep 1978 CA
2520986 Apr 2000 CA
3059529 Oct 2018 CA
3059527 Oct 2019 CA
1216780 May 1999 CN
1216781 May 1999 CN
1106448 Apr 2003 CN
1449741 Oct 2003 CN
1584596 Feb 2005 CN
1602716 Apr 2005 CN
1609188 Apr 2005 CN
1644675 Jul 2005 CN
1289532 Aug 2005 CN
1313498 Aug 2005 CN
1651467 Aug 2005 CN
1651468 Aug 2005 CN
1654482 Aug 2005 CN
1680571 Oct 2005 CN
1696302 Nov 2005 CN
1723904 Jan 2006 CN
1768860 May 2006 CN
1264976 Jul 2006 CN
1948347 Apr 2007 CN
1315873 May 2007 CN
101036788 Sep 2007 CN
101069677 Nov 2007 CN
101088879 Dec 2007 CN
101100687 Jan 2008 CN
101229379 Jul 2008 CN
101254309 Sep 2008 CN
101283774 Oct 2008 CN
101416930 Apr 2009 CN
101555507 Oct 2009 CN
101560528 Oct 2009 CN
100571781 Dec 2009 CN
101653171 Feb 2010 CN
101096236 May 2010 CN
101731410 Jun 2010 CN
101755991 Jun 2010 CN
101760456 Jun 2010 CN
101831000 Sep 2010 CN
101836678 Sep 2010 CN
101839849 Sep 2010 CN
101942493 Jan 2011 CN
101988036 Mar 2011 CN
101279096 Apr 2011 CN
102010526 Apr 2011 CN
102027999 Apr 2011 CN
101215592 Aug 2011 CN
102258484 Nov 2011 CN
101974543 May 2012 CN
102492630 Jun 2012 CN
101579326 Jul 2012 CN
102552721 Jul 2012 CN
102626279 Aug 2012 CN
102670563 Sep 2012 CN
102766219 Nov 2012 CN
102010513 Jan 2013 CN
102875742 Jan 2013 CN
101669670 Feb 2013 CN
102432921 Apr 2013 CN
103015175 Apr 2013 CN
103030978 Apr 2013 CN
102499451 May 2013 CN
101487034 Jun 2013 CN
102499910 Jun 2013 CN
102492740 Aug 2013 CN
103243135 Aug 2013 CN
102145173 Oct 2013 CN
102600493 Dec 2013 CN
103503983 Dec 2013 CN
102603912 Jan 2014 CN
103060204 Feb 2014 CN
103570842 Feb 2014 CN
102531773 Mar 2014 CN
103626885 Mar 2014 CN
103636743 Mar 2014 CN
103642086 Mar 2014 CN
102783713 Apr 2014 CN
103695476 Apr 2014 CN
103695500 Apr 2014 CN
103724709 Apr 2014 CN
103740785 Apr 2014 CN
103798253 May 2014 CN
103805650 May 2014 CN
103805651 May 2014 CN
103806275 May 2014 CN
103880762 Jun 2014 CN
103881927 Jun 2014 CN
103882076 Jun 2014 CN
102994395 Jul 2014 CN
103893107 Jul 2014 CN
103088085 Aug 2014 CN
103961334 Aug 2014 CN
103961335 Aug 2014 CN
103993042 Aug 2014 CN
103305569 Sep 2014 CN
104059560 Sep 2014 CN
104082851 Oct 2014 CN
103409480 Nov 2014 CN
104222265 Dec 2014 CN
103172757 Jan 2015 CN
103255067 Jan 2015 CN
103451108 Jan 2015 CN
104256251 Jan 2015 CN
103416694 Feb 2015 CN
104401075 Mar 2015 CN
104403135 Mar 2015 CN
104432492 Mar 2015 CN
104436204 Mar 2015 CN
104448019 Mar 2015 CN
104448403 Mar 2015 CN
104450827 Mar 2015 CN
104473822 Apr 2015 CN
104479038 Apr 2015 CN
104609992 May 2015 CN
104611783 May 2015 CN
104651405 May 2015 CN
104694404 Jun 2015 CN
104711374 Jun 2015 CN
104725652 Jun 2015 CN
103163128 Jul 2015 CN
104762753 Jul 2015 CN
104798975 Jul 2015 CN
104799145 Jul 2015 CN
104824508 Aug 2015 CN
104840447 Aug 2015 CN
104844810 Aug 2015 CN
104857560 Aug 2015 CN
104859237 Aug 2015 CN
104861178 Aug 2015 CN
104861214 Aug 2015 CN
104861246 Aug 2015 CN
102552191 Sep 2015 CN
104906622 Sep 2015 CN
104911231 Sep 2015 CN
104911232 Sep 2015 CN
104927266 Sep 2015 CN
102964849 Oct 2015 CN
103351629 Nov 2015 CN
105028864 Nov 2015 CN
105039276 Nov 2015 CN
105039281 Nov 2015 CN
105055365 Nov 2015 CN
105106181 Dec 2015 CN
105267060 Jan 2016 CN
103789363 Feb 2016 CN
110678170 Jan 2020 CN
110678555 Jan 2020 CN
200778 Sep 1980 CS
2504108 Jan 1976 DE
3147193 Jun 1983 DE
261609 Nov 1988 DE
0143603 Jun 1985 EP
0164933 Dec 1985 EP
0216221 Apr 1987 EP
0222302 May 1987 EP
0236124 Sep 1987 EP
0267788 May 1988 EP
0289138 Nov 1988 EP
0313993 May 1989 EP
0319372 Jun 1989 EP
0189461 Jul 1990 EP
0379378 Jul 1990 EP
0382355 Aug 1990 EP
0402092 Dec 1990 EP
0405283 Jan 1991 EP
0418835 Mar 1991 EP
0450627 Oct 1991 EP
0450767 Oct 1991 EP
0482576 Apr 1992 EP
0514008 Nov 1992 EP
0538049 Apr 1993 EP
0559450 Sep 1993 EP
0565106 Oct 1993 EP
0586034 Mar 1994 EP
0600730 Jun 1994 EP
0661294 Jul 1995 EP
0670368 Sep 1995 EP
0757049 Feb 1997 EP
0761692 Mar 1997 EP
0812919 Dec 1997 EP
0653931 Sep 1999 EP
1072633 Jan 2001 EP
0714656 Feb 2001 EP
1106347 Jun 2001 EP
1157691 Nov 2001 EP
1166745 Jan 2002 EP
1308505 May 2003 EP
1335020 Aug 2003 EP
1398346 Mar 2004 EP
0784688 Jul 2004 EP
1454918 Sep 2004 EP
1454950 Sep 2004 EP
1621211 Feb 2006 EP
1698239 Sep 2006 EP
1873254 Jan 2008 EP
1117736 Aug 2008 EP
2135883 Dec 2009 EP
2151500 Feb 2010 EP
2447269 May 2012 EP
2583982 Apr 2013 EP
2663294 Nov 2013 EP
2683830 Jan 2014 EP
3609476 Feb 2020 EP
3610028 Feb 2020 EP
2167986 Aug 1973 FR
2259905 Aug 1975 FR
2276007 Jan 1976 FR
2362888 Mar 1978 FR
2517326 Jun 1983 FR
2528060 Dec 1983 FR
2817264 May 2002 FR
1260418 Jan 1972 GB
1443918 Jul 1976 GB
1493411 Nov 1977 GB
1496017 Dec 1977 GB
1502797 Mar 1978 GB
1559644 Jan 1980 GB
2109391 Jun 1983 GB
2173088 Oct 1986 GB
0434DEL2001 Sep 2008 IN
2718BOM2009 Feb 2012 IN
1374DEL2012 May 2012 IN
S4821739 Mar 1973 JP
S497492 Jan 1974 JP
S4983779 Aug 1974 JP
S49117688 Nov 1974 JP
S5019943 Mar 1975 JP
S50105887 Aug 1975 JP
S50108357 Aug 1975 JP
S50123931 Sep 1975 JP
S50148490 Nov 1975 JP
S511699 Jan 1976 JP
S517189 Jan 1976 JP
S5144163 Apr 1976 JP
S5152484 May 1976 JP
S52109535 Sep 1977 JP
S52130993 Nov 1977 JP
S5326867 Mar 1978 JP
S5379972 Jul 1978 JP
S5437888 Mar 1979 JP
S5437889 Mar 1979 JP
S55118369 Sep 1980 JP
S56147801 Nov 1981 JP
S5894364 Jun 1983 JP
S59172566 Sep 1984 JP
S61171405 Aug 1986 JP
S61263915 Nov 1986 JP
S6262521 Mar 1987 JP
S63283593 Nov 1988 JP
H01197432 Aug 1989 JP
H0321602 Jan 1991 JP
H0515368 Jan 1993 JP
H0525201 Feb 1993 JP
H0565222 Mar 1993 JP
H0594667 Apr 1993 JP
H05111364 May 1993 JP
H05148303 Jun 1993 JP
H05328988 Dec 1993 JP
H0665302 Mar 1994 JP
H06157313 Jun 1994 JP
H0710901 Jan 1995 JP
H0725891 Jan 1995 JP
H0725903 Jan 1995 JP
H0759585 Mar 1995 JP
H0790250 Apr 1995 JP
H0847378 Feb 1996 JP
H08175983 Jul 1996 JP
H08205865 Aug 1996 JP
H093106 Jan 1997 JP
H10155697 Jun 1998 JP
H10215892 Aug 1998 JP
H10229839 Sep 1998 JP
H1139450 Feb 1999 JP
H1195405 Apr 1999 JP
H11240806 Sep 1999 JP
2000041583 Feb 2000 JP
2000202003 Jul 2000 JP
2000294439 Oct 2000 JP
2000327699 Nov 2000 JP
2000348958 Dec 2000 JP
2001048765 Feb 2001 JP
2001095514 Apr 2001 JP
2001191446 Jul 2001 JP
2001250733 Sep 2001 JP
2001316237 Nov 2001 JP
2002033231 Jan 2002 JP
2002045118 Feb 2002 JP
2003134971 May 2003 JP
2003238151 Aug 2003 JP
2003265111 Sep 2003 JP
2003310295 Nov 2003 JP
2003313145 Nov 2003 JP
2004097233 Apr 2004 JP
2004306534 Nov 2004 JP
2005112744 Apr 2005 JP
2005137935 Jun 2005 JP
2005298644 Oct 2005 JP
2005302320 Oct 2005 JP
2005341958 Dec 2005 JP
2006026544 Feb 2006 JP
2006101714 Apr 2006 JP
2006143808 Jun 2006 JP
2006247505 Sep 2006 JP
2007006978 Jan 2007 JP
2007089569 Apr 2007 JP
2007238908 Sep 2007 JP
2007321003 Dec 2007 JP
2007536308 Dec 2007 JP
2008011807 Jan 2008 JP
2008050542 Mar 2008 JP
2008133186 Jun 2008 JP
2008162966 Jul 2008 JP
2008208092 Sep 2008 JP
2008208120 Sep 2008 JP
2008266458 Nov 2008 JP
2009039064 Feb 2009 JP
2009161522 Jul 2009 JP
2009185022 Aug 2009 JP
2009232818 Oct 2009 JP
2009233170 Oct 2009 JP
2010051327 Mar 2010 JP
2010053122 Mar 2010 JP
2010158253 Jul 2010 JP
2010523594 Jul 2010 JP
2010227042 Oct 2010 JP
2011182709 Sep 2011 JP
2012015152 Jan 2012 JP
2012016309 Jan 2012 JP
2012017326 Jan 2012 JP
2012062279 Mar 2012 JP
2012167273 Sep 2012 JP
2013000111 Jan 2013 JP
2015048316 Mar 2015 JP
2015177783 Oct 2015 JP
2020512827 Apr 2020 JP
2020516653 Jun 2020 JP
19890003762 Apr 1989 KR
19940014797 Jul 1994 KR
19970062047 Feb 1996 KR
20010083600 Sep 2001 KR
20020066298 Aug 2002 KR
100508434 Aug 2005 KR
100739022 Jul 2007 KR
20100100496 Mar 2009 KR
20090036797 Apr 2009 KR
20110037739 Apr 2011 KR
20110089044 Aug 2011 KR
20120064008 Jun 2012 KR
164352 Jul 1994 PL
90437 Oct 1986 RO
105830 Dec 1992 RO
116203 Nov 2000 RO
116212 Nov 2000 RO
20080223 Apr 2011 RS
1559718 Dec 1994 RU
2034923 May 1995 RU
WO9808399 Mar 1998 WO
WO0047190 Aug 2000 WO
WO0054606 Sep 2000 WO
WO0107507 Feb 2001 WO
WO0246241 Jun 2002 WO
WO02072862 Sep 2002 WO
WO03039522 May 2003 WO
WO03105605 Dec 2003 WO
WO2004012720 Feb 2004 WO
WO2004041926 May 2004 WO
WO2004056336 Jul 2004 WO
WO2004078959 Sep 2004 WO
WO2004096182 Nov 2004 WO
WO2004096283 Nov 2004 WO
WO2005006874 Jan 2005 WO
WO2005016315 Feb 2005 WO
WO2005020979 Mar 2005 WO
WO2005079751 Sep 2005 WO
WO2005082330 Sep 2005 WO
WO2005084433 Sep 2005 WO
WO2005105051 Nov 2005 WO
WO2006018814 Feb 2006 WO
WO2006033942 Mar 2006 WO
WO2006082842 Aug 2006 WO
WO2007011222 Jan 2007 WO
WO2007095977 Aug 2007 WO
WO2008047846 Apr 2008 WO
WO2008101894 Aug 2008 WO
WO2008124617 Oct 2008 WO
WO2008137832 Nov 2008 WO
WO2009050646 Apr 2009 WO
WO2009123257 Oct 2009 WO
WO2009138920 Nov 2009 WO
WO2009154320 Dec 2009 WO
WO2010139100 Dec 2010 WO
WO2013085021 Jun 2013 WO
WO2013123623 Aug 2013 WO
WO2013146669 Oct 2013 WO
WO2013162707 Oct 2013 WO
WO2014000425 Jan 2014 WO
WO2014051023 Apr 2014 WO
WO2014072716 May 2014 WO
WO2014209246 Dec 2014 WO
WO2015092939 Jun 2015 WO
WO2015133439 Sep 2015 WO
WO2018189584 Oct 2018 WO
WO2018189587 Oct 2018 WO
Non-Patent Literature Citations (19)
Entry
Bouvens, H.O. et al., “Polysaccharides elaborated by Pullularia pullulans; Part I. The neutral glucan synthesized from sucrose solutions,” Acta Chemica Scandinavica, 16(3):615-622 (1962).
Cade et al., “Liquid Filling in Hard Gelatin Capsules—Preliminary Steps,” Bulletin Technique Gattefosse, 89:15-19 (1996).
European Patent Office Communication dated May 2, 2014, from EPC Patent Application No. 12705407.0 (6 pages).
International Search Report for PCT/IB2012/000176 (dated Aug. 7, 2012).
International Search Report and Written Opinion for PCT/IB2018/000457 (dated Sep. 10, 2018).
Madi, N. et al., “Effect of exogenous calcium on morphological development and biopolymer synthesis in the fungus Aureobasidium pullulans,” Enzyme and Microbial Technology, 21(2):102-107 (Aug. 1997).
Millender, “Capsule Shell Composition and Manufacturing,” in Multiparticulate Oral Drug Delivery. Drugs and the Pharmaceutical Sciences, 65:357-383, New York, New York, USA: Marcel Dekker, Inc., 1994.
Morris, “Quantitative determination of carbohydrates with Dreywood's anthrone reagent,” Science, 107:254-255 (Mar. 1948).
Notice of Reasons for Rejection dated May 12, 2015, from related Japanese Patent Application No. 2013-548905, with English-language translation (9 pages).
“Opinion of the Scientific Panel on Food Additives, Flavourings, Processing Aids, and Materials in Contact with Food on a Request from the Commission related to Pullulan PI-20 for use as a new food additive,” The EFSA Journal, vol. 85, pp. 1-32, (Jul. 13, 2004).
Petition for Inter Partes Review of U.S. Pat. No. 6,887,307, filed Jul. 27, 2015.
Petition for Inter Partes Review of U.S. Pat. No. 7,267,718, filed Jul. 27, 2015.
“Pullulan,” Official Monographs, USP 32-NF 27, 1330-1331, Dec. 1, 2008.
Seo, H. et al., “Production of high molecular weight pullulan by Aureobasidium pullulans HP-2001 with soybean pomace as nitrogen source,” Bioresource Technology, 95(3):293-299 (Dec. 2004).
Tarcha, Polymers for Controlled Drug Delivery, CRC Press, p. 55, 1991.
Written Opinion for PCT/IB2012/000176 (dated Aug. 7, 2012).
International Search Report and Written Opinion for PCT/IB2018/000448 (dated Jul. 17, 2018).
Office Action for European Application No. 18724311.8, dated Nov. 6, 2020.
Xiao, Hong-Su et al., “Phenotypic Plasticity in Aureobasidium pullulans Isolates,” International Journal of Agricultural & Biology, 22(1):167-177 (Jan. 2019).
Related Publications (1)
Number Date Country
20200289422 A1 Sep 2020 US
Provisional Applications (1)
Number Date Country
62485854 Apr 2017 US